These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 21612550)

  • 21. Lysosomal storage diseases: current therapies and future alternatives.
    Leal AF; Espejo-Mojica AJ; Sánchez OF; Ramírez CM; Reyes LH; Cruz JC; Alméciga-Díaz CJ
    J Mol Med (Berl); 2020 Jul; 98(7):931-946. PubMed ID: 32529345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement.
    Nascimbeni F; Dionisi Vici C; Vespasiani Gentilucci U; Angelico F; Nobili V; Petta S; Valenti L;
    Dig Liver Dis; 2020 Apr; 52(4):359-367. PubMed ID: 31902560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic approaches for lysosomal storage diseases: a patent update.
    Urbanelli L; Sagini K; Polidoro M; Brozzi A; Magini A; Emiliani C
    Recent Pat CNS Drug Discov; 2013 Aug; 8(2):91-109. PubMed ID: 23713988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclodextrin-based iminosugar click clusters: the first examples of multivalent pharmacological chaperones for the treatment of lysosomal storage disorders.
    Decroocq C; Rodríguez-Lucena D; Ikeda K; Asano N; Compain P
    Chembiochem; 2012 Mar; 13(5):661-4. PubMed ID: 22344719
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment for Lysosomal Storage Disorders.
    Sheth J; Nair A
    Curr Pharm Des; 2020; 26(40):5110-5118. PubMed ID: 33059565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glyco-engineering strategies for the development of therapeutic enzymes with improved efficacy for the treatment of lysosomal storage diseases.
    Oh DB
    BMB Rep; 2015 Aug; 48(8):438-44. PubMed ID: 25999178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current treatment options and novel nanotechnology-driven enzyme replacement strategies for lysosomal storage disorders.
    Del Grosso A; Parlanti G; Mezzena R; Cecchini M
    Adv Drug Deliv Rev; 2022 Sep; 188():114464. PubMed ID: 35878795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Development of Enzyme Drugs Derived from Transgenic Silkworms to Treat Lysosomal Diseases].
    Itoh K; Nishioka SI; Hidaka T; Tsuji D; Maita N
    Yakugaku Zasshi; 2018; 138(7):885-893. PubMed ID: 29962464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on treatment of lysosomal storage diseases.
    Bruni S; Loschi L; Incerti C; Gabrielli O; Coppa GV
    Acta Myol; 2007 Jul; 26(1):87-92. PubMed ID: 17915580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification.
    Keyzor I; Shohet S; Castelli J; Sitaraman S; Veleva-Rotse B; Weimer JM; Fox B; Willer T; Tuske S; Crathorne L; Belzar KJ
    Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lysosomal storage diseases.
    Platt FM; d'Azzo A; Davidson BL; Neufeld EF; Tifft CJ
    Nat Rev Dis Primers; 2018 Oct; 4(1):27. PubMed ID: 30275469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second-Generation Pharmacological Chaperones: Beyond Inhibitors.
    Tran ML; Génisson Y; Ballereau S; Dehoux C
    Molecules; 2020 Jul; 25(14):. PubMed ID: 32660097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chaperone therapy for molecular pathology in lysosomal diseases.
    Suzuki Y
    Brain Dev; 2021 Jan; 43(1):45-54. PubMed ID: 32736903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New strategies for the treatment of lysosomal storage diseases (review).
    Parenti G; Pignata C; Vajro P; Salerno M
    Int J Mol Med; 2013 Jan; 31(1):11-20. PubMed ID: 23165354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral small molecule therapy for lysosomal storage diseases.
    Weinreb NJ
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():77-90. PubMed ID: 24380126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders.
    Desnick RJ; Schuchman EH
    Nat Rev Genet; 2002 Dec; 3(12):954-66. PubMed ID: 12459725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clarifying lysosomal storage diseases.
    Schultz ML; Tecedor L; Chang M; Davidson BL
    Trends Neurosci; 2011 Aug; 34(8):401-10. PubMed ID: 21723623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases.
    Shayman JA; Larsen SD
    J Lipid Res; 2014 Jul; 55(7):1215-25. PubMed ID: 24534703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment strategies for lysosomal storage disorders.
    Beck M
    Dev Med Child Neurol; 2018 Jan; 60(1):13-18. PubMed ID: 29090451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem.
    Macauley SL
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1(Suppl 1):639-48. PubMed ID: 27491211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.